KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Vertex Pharmaceuticals (VRTX) EBIT Margin: 2009-2025

Historic EBIT Margin for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Sep 2025 value amounting to 38.56%.

  • Vertex Pharmaceuticals' EBIT Margin fell 171.00% to 38.56% in Q3 2025 from the same period last year, while for Sep 2025 it was 34.06%, marking a year-over-year increase of 3661.00%. This contributed to the annual value of -2.11% for FY2024, which is 4094.00% down from last year.
  • Vertex Pharmaceuticals' EBIT Margin amounted to 38.56% in Q3 2025, which was down 0.69% from 38.83% recorded in Q2 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' EBIT Margin peaked at 53.15% during Q3 2021, and registered a low of -132.85% during Q2 2024.
  • Moreover, its 3-year median value for EBIT Margin was 38.83% (2025), whereas its average is 21.83%.
  • Per our database at Business Quant, Vertex Pharmaceuticals' EBIT Margin slumped by 17,402bps in 2024 and then spiked by 17,168bps in 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' EBIT Margin (Quarterly) stood at 42.35% in 2021, then soared by 253bps to 44.88% in 2022, then slumped by 562bps to 39.26% in 2023, then slumped by 403bps to 35.23% in 2024, then tumbled by 171bps to 38.56% in 2025.
  • Its last three reported values are 38.56% in Q3 2025, 38.83% for Q2 2025, and 22.75% during Q1 2025.